Key Takeaways BMY's growth drugs like Opdivo, Reblozyl, Camzyos and Cobenfy help offset legacy drug declines. GSK's HIV, oncology, and respiratory drugs, plus new vaccine approvals, fuel top-line growth. GSK shares have risen 18.5% YTD, outpacing BMYs 14.3% decline, with both stocks rated Hold.Bristol Myers Squibb ((BMY) and GSK PLC ((GSK) are among the largest global biopharma companies with broad and diverse portfolios.Bristol Myers is focused on discovering, developing and delivering transformational dru ...